Bayer Beefs Up Biologics Pipeline With Direvo Biotech Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Separate spin-out transaction establishes Direvo’s industrial biotech business as an independent entity.
You may also be interested in...
Direvo CEO Thomas von Ruden: An Interview With “The Pink Sheet” DAILY
In first installment of interview, von Ruden discusses Direvo’s technology focus and how it came to center on Factor VIII and Factor IX.
Direvo CEO Thomas von Ruden: An Interview With “The Pink Sheet” DAILY
In first installment of interview, von Ruden discusses Direvo’s technology focus and how it came to center on Factor VIII and Factor IX.
Bayer Builds On Oncology Pipeline With Nycomed’s Divested Kinase Inhibitors
Acquisition of two candidates and back-up compounds complements ongoing Nexavar efforts, Bayer says.